INS018_055 not checked
InSilico Medicine Hong Kong Limited
FollowEvery change as it happens, and a Monday email
Trials
2 active
4 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Dosage form: Tablets; Frequency of administration: Orally QD. Other Names: Rentosertib”In the company’s words, NCT07687459 on ClinicalTrials.gov
- Main trialPhase 3
- “This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018\_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis. The purpose of this study is to evaluate if Rentosertib (INS018\_055) works to treat patients with Idiopathic Pulmonary Fibrosis in adults. It will also learn about the safety of Rentosertib (INS018\_055). In this study, Rentosertib (INS018\_055) will be compared to a placebo (a look-alike substance that contains no drug) to investigate if Rentosertib (INS018\_055) works…”In the company’s words, NCT07687459 on ClinicalTrials.gov
Other drugs for Idiopathic Pulmonary Fibrosis
- SC1011JOYO Pharma · Phase 2/3
- NerandomilastBoehringer Ingelheim · Phase 3
- NAL ERTrevi Therapeutics · Phase 3
- AK3280Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 3
- TDI01Beijing Tide Pharmaceutical Co., Ltd · Phase 3
- AdmilparantBristol Myers Squibb · Phase 3
Coming up1
- 30 Oct 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Oct 2029 | Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF) | |
| Phase 2Recruiting | 28 Feb 2026 | Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis | |
| Phase 2Completed | 8 Aug 2024 | Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF) | |
| Phase 1Completed | 2 Dec 2022 | A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026